Melissa Palmer, MD

Melissa Palmer, MD is an internationally renowned Hepatologist (KOL), CEO of Liver Consulting LLC and an experienced biotech/pharma executive. Dr. Palmer provides services as a Hepatology consultant for all types of liver diseases. Dr. Palmer is an experienced MASH consultant, DILI consultant, PSC consultant, Alcoholic hepatitis consultant and drug development consultant to the pharmaceutical industry. Dr Palmer is currently consulting on innovative trial designs for MASH and other liver diseases such as PSC, and acute on chronic liver failure, regulatory consultant (having co-authored numerous guidelines with FDA colleagues ), and DILI. In addition, skills include formation of and sitting on advisory boards, DSMCs, commercialization and pipeline assessment, leading matrix teams etc.
Dr. Palmer was in a solo practice devoted to treating patients with liver disease from 1991-2009, at which time she became Clinical Professor at NYU Langone/ Director of Hepatology at NYU Plainview. From 1991-2011 she was a consultant to > 40 biopharma companies as a liver disease expert. Dr. Palmer left NYU Langone to become SVP Clinical Research and Head of Hepatology at Kadmon Corporation.
Dr. Palmer left Kadmon in 2015 to become Global Lead on Shire's NASH program, as well as other liver-related issues within the company, such as orphan cholestatic liver diseases PFIC Alagilles, PSC and PBC, and liver-related safety issues (DILI), and was rapidly promoted to Global Development Lead - Hepatology and led the formation of the liver safety group. Shire was acquired by Takeda in 2019 at which time Dr. Palmer was recruited as Head of Liver Disease Development at Takeda.
Dr. Palmer graduated from Columbia University with a B.A. and was trained in Hepatology (as well as medical school) at Mount Sinai School of Medicine in New York City. She has authored numerous medical and lay-public books and book chapters and contributed to three encyclopedias on liver-related topics. Her scientific publications have appeared in such peer-reviewed journals as Hepatology, Gastroenterology, Seminars of Liver Disease, Transplantation, AP&T and she is a contributing editor of several peer-reviewed journals. She has been on the NY ALF medical advisory board for >35 yrs.
Specialties: Hepatology consultant, MASLD/MASH consultant, Clinical Research, Clinical trial Innovation. Drug Development consultant, Drug-Induced Liver Injury (DILI ) consulting, Primary Biliary Cholangitis consultant, Primary Sclerosing Cholangitis consultant, Hepatitis B and C and Alcoholic Hepatitis Consultant